Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients. Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity. The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.
Location: United States, Pennsylvania, Hatfield Township
Employees: 11-50
Total raised: $85M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 07.07.2021 | New Enterp... | nea.com |
| 06.02.2022 | Takeda Ven... | takeda.com |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 09.06.2022 | Series A | $75M | - | vcnewsdail... |
| 20.04.2021 | Seed | $10M | - | marketscre... |
Mentions in press and media 10
| Date | Title | Description | Source |
| 09.06.2022 | Code Biotherapeutics Raises $75M in Series A | HATFIELD, PA, Code Biotherapeutics, a biotechnology company, announced its Series A financing of $... | vcnewsdail... |
| 08.06.2022 | Code Biotherapeutics Raises $75 Million in Series A Financin... | Code Biotherapeutics, a Greater Philadelphia, PA-based biotechnology company advancing targeted non-... | finsmes.co... |
| 07.06.2022 | Code Biotherapeutics Raises Upsized and Oversubscribed $75 M... | Greater Philadelphia, Pa., June 7, 2022 — Code Biotherapeutics, Inc., (Code Bio), a biotechnology co... | ucbventure... |
| 07.06.2022 | 4BIO Capital Portfolio Company Code Biotherapeutics Closes U... | Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed... | globenewsw... |
| 01.03.2022 | Code Biotherapeutics Announces Collaboration with Takeda | Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral deliver... | 4biocapita... |
| 20.04.2021 | 4BIO Capital Co-leads $10 Million Seed Financing in Code Bio... | Press Release 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics 20 April 20... | marketscre... |
| 20.04.2021 | Code Biotherapeutics Launches with $10 Million in Seed Finan... | Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of tar... | marketscre... |
| 20.04.2021 | 4BIO Capital Co-leads $10 Million Seed Financing in Code Bio... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... | 4biocapita... |
| 09.11.2015 | NEA joins a $35M round for a Wellcome-backed gene therapy pl... | After posting some early clinical success with its first gene therapy project, University of Oxford ... | fiercebiot... |
| - | 4BIO Capital Portfolio Company Code Biotherapeutics Closes a... | London & Greater Philadelphia – 4BIO Capital (“4BIO” or “the Group”), an international venture c... | 4biocapita... |